Forcefield Therapeutics

Forcefield Therapeutics is a biotechnology company developing protein-based therapeutics to protect heart muscle following acute myocardial infarction.

The company's approach uses naturally occurring cardioprotective proteins, discovered at King's College London, that can preserve cardiomyocytes and prevent the cascade of damage leading to heart failure.

Forcefield operates a virtual model and is backed by Syncona. Its pipeline targets acute post-heart attack intervention, an area with significant unmet clinical need.